RFA-CA-22-031: Consortium on Translational Research in Early Detection of Liver Cancer: Translational Research Centers (U01 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $550,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 5 awards worth $4.4 million in total. Applications closed on November 7, 2022.
From the official notice on Grants.gov, last changed August 16, 2022. Checked November 7, 2026.
- Award ceiling$550,000
- Total funding$4.4 million
- Expected awards5
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsOptional
- Funded byNCI
- Median yearly award$855,282
- Typical project length7.5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-CA-22-031 were run by National Cancer Institute (NCI, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-22-031 in the NIH Guide.
Key dates
| Posted | August 15, 2022 |
|---|---|
| Deadline | November 7, 2022 |
| Archived by Grants.gov | December 13, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $855,282; it allows up to $550,000 per award.
- Most of the program's money (61% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) is soliciting applications for a Liver Cancer Consortium focused on advancing translational research in the early detection of liver cancer. Translational Research Centers (TRCs) will conduct studies to improve the surveillance of liver cancer in members of high-risk populations, increase the fraction of liver cancer detected at an early stage, and better stratify patients at risk of developing liver cancer. A major collaborative effort of the TRCs will be establishing an integrated blood and image repository with annotated clinical data from patients found to have indeterminate nodules during liver cancer surveillance. To achieve these goals, each proposed TRC should include laboratory and clinical researchers with multi-disciplinary expertise in such areas as early cancer detection, biomarkers, cancer surveillance, imaging, and biospecimen science. The Consortium will consist of several Translational Research Centers (TRCs, to be supported by this U01 FOA) and a Data Management and Coordinating Center (DMCC, to be supported a companion U24 FOA, RFA-CA-21-032). The TRCs will be expected to interact closely with the DMCC and engage in collaborative activities with other members of the Liver Cancer Consortium.
Funded under RFA-CA-22-031 so far
NIH funded 4 projects under RFA-CA-22-031 in fiscal 2023 to 2026, at 4 institutions. The median yearly award was $855,282.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Risk Stratification for and Early Detection of Liver Cancer | Baylor College of Medicine | 2026 | $766,080 |
| The UCLA Center in Early Detection of Liver Cancer | University of California Los Angeles | 2026 | $866,250 |
| Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver Nodules | UT Southwestern Medical Center | 2025 | $2.1 million |
| Liquid biopsy and radiomics for liver cancer surveillance | Icahn School of Medicine at Mount Sinai | 2025 | $2.0 million |
Who has won Cancer Detection and Diagnosis Research grants before
From fiscal 2021 to 2025, Cancer Detection and Diagnosis Research (93.394) awarded $2.7 billion across 1,944 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 56 | $114 million |
| Fred Hutchinson Cancer Center | Washington | 37 | $96.7 million |
| The Leland Stanford Junior University | California | 62 | $89.1 million |
| Sloan-Kettering Institute for Cancer Research | New York | 52 | $88.7 million |
| The Johns Hopkins University | Maryland | 63 | $86.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-22-031 still open?
No. It closed on November 7, 2022.
Who can apply for Consortium on Translational Research in Early Detection of Liver Cancer: Translational Research Centers (U01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Consortium on Translational Research in Early Detection of Liver Cancer: Translational Research Centers (U01 Clinical Trial Optional)?
Closed November 7, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $550,000 each. About $4.4 million in total across about 5 awards.
Who has been funded under RFA-CA-22-031?
NIH RePORTER lists 4 projects funded under RFA-CA-22-031 in fiscal 2023 to 2026, at 4 institutions. The most were at Baylor College of Medicine, University of California Los Angeles, UT Southwestern Medical Center.
Who has won Cancer Detection and Diagnosis Research grants before?
The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, Fred Hutchinson Cancer Center, The Leland Stanford Junior University. The program made 1,944 awards worth $2.7 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)